Maridebart cafraglutide
InvestigationalGLP-1 agonist and GIPR antagonist
Also known as: MariTide, AMG 133
A real evidence base, with gaps
- Regulatory standing. In clinical trials, not yet approved
- Limited human data. Some human data exists, not conclusive
- Registered human trials. 28 registered studies on ClinicalTrials.gov, most advanced Phase 3
- No sources. Nothing cited to verify
Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.
What it is
Maridebart cafraglutide, also known as MariTide or AMG 133, is an investigational drug developed by Amgen for obesity and related metabolic conditions. It is an antibody-peptide conjugate that combines a monoclonal antibody blocking the GIP receptor with attached peptides that activate the GLP-1 receptor. The long-acting antibody design is intended to allow infrequent administration.
What the evidence shows
It is not FDA-approved. Early and mid-stage human trials have reported weight loss, and 26 registered trials include Phase 3 studies, but long-term efficacy and safety are not yet established.
Registered human trials
Live from ClinicalTrials.gov, refreshed daily.
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the Body
Effect of Maridebart Cafraglutide on the Heart's Electrical Activity
Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants
Published literature
Live from Europe PMC. This is how much has been published, not how much is proven in humans.
A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings.
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial.
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.
A metabolic comparison of GIPR agonism versus GIPR antagonism in male mice.
Sources
Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.